Updated:
PEAL Investment Partners
PEAL Investment Partners, led by Karen O'Mahony, runs the only dedicated longevity and hormonal health private equity strategy in Europe.
PEAL Investment Partners
Private equity in longevity and hormonal health, investing in innovative medical businesses with hands-on growth expertise.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
111 Park Street, London, W1K 7JF
Additional offices
Zug, Switzerland · Dublin, Ireland
Principals
Karen O'Mahony
Founder & Managing Partner
Brendan McDonagh
Chair of PEAL Capital Group
Tara Mandal
Partner & COO
Ian Buchanan
Investment Committee Member
June Aitken
Investment Committee Member
Lynda Hayden
Head of Operations
William Knowles
PEAL Group Director
Leila Khazaneh
General Counsel
Sarah Rist
Investment Director
Sector focus
Frequently asked questions
What makes PEAL Investment Partners' investment strategy unique?
PEAL is the only private equity firm dedicated exclusively to the longevity and hormone health sector, deploying a three-fund strategy that spans the full supply chain. The firm takes controlling or influential minority stakes in lower-mid-cap businesses and provides hands-on operational support from acquisition to exit. This singular focus aims to capture proprietary off-market opportunities across clinics, education, and ancillary services.
Who makes investment decisions at PEAL?
Investment decisions are led by Founder and Managing Partner Karen O'Mahony, supported by Partner and COO Tara Mandal and Investment Director Sarah Rist. An investment committee that includes Ian Buchanan and June Aitken provides additional oversight on commitments.
What types of companies does PEAL invest in?
PEAL targets mature lower-mid-cap businesses in the longevity, menopause, and hormonal health sectors. Its publicly disclosed portfolio includes clinical services provider Apex Clinics Ltd, education company Newson Education, and aesthetics training provider Derma Med Ltd. The firm typically seeks controlling or influential minority positions with a hands-on operational engagement model.
Where does PEAL deploy capital geographically?
PEAL states that its investments reach the UK, Western Europe, Australia, and North America. The firm's corporate structure includes entities in London, Dublin, and Zug, Switzerland, supporting its cross-border deal activity.
Does PEAL raise capital from outside investors or act as a single family office?
PEAL Investment Partners operates as an asset manager raising third-party capital, not a single family office. The firm does not publicly disclose its fund sizes or limited partner base, but its external-facing materials actively invite investor engagement and co-investment interest.
What is PEAL's relationship to the PEAL Capital Group entities?
PEAL Investment Partners is part of the PEAL Capital Group structure, which includes separate legal entities in the UK, Switzerland, and Ireland. The Group coordinates the firm's investment vehicles and operational oversight, with Brendan McDonagh serving as Chair of the overarching group.
How does PEAL support portfolio companies after acquisition?
PEAL delivers hands-on operational and financial support, embedding senior team members into active governance roles rather than relying solely on external consulting resources. The firm highlights its 'building agility' and value creation playbook as central to the post-acquisition phase, and it points to initiatives like portfolio company Derma Medical's DermaHub launch as evidence of its operating-partner model in action.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: